Effects of Pimobendan on Prolonging Time to Rehospitalization or Frequency of Rehospitalization in Patients with Heart Failure: A Retrospective Cohort Study Using a Medical Administrative Database (PREFER Study)

**Background:** As approximately 24% of patients with chronic heart failure are rehospitalized within 1 year and heart failure is aggravated by repeated hospitalizations, greater importance was attached to the prevention of hospitalization. **Objective:** The objective of this study was to investig...

Full description

Saved in:
Bibliographic Details
Main Authors: Kazuhisa Kodama, Tatsunori Murata, Naoki Dohi, Masaaki Nakano, Toshiaki Yokoi, Tomohiro Sakamoto, Koichi Nakao
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2020-06-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/jheor.2020.13246
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823860389764399104
author Kazuhisa Kodama
Tatsunori Murata
Naoki Dohi
Masaaki Nakano
Toshiaki Yokoi
Tomohiro Sakamoto
Koichi Nakao
author_facet Kazuhisa Kodama
Tatsunori Murata
Naoki Dohi
Masaaki Nakano
Toshiaki Yokoi
Tomohiro Sakamoto
Koichi Nakao
author_sort Kazuhisa Kodama
collection DOAJ
description **Background:** As approximately 24% of patients with chronic heart failure are rehospitalized within 1 year and heart failure is aggravated by repeated hospitalizations, greater importance was attached to the prevention of hospitalization. **Objective:** The objective of this study was to investigate the influence of pimobendan on rehospitalization of patients with advanced heart failure using a Japanese medical administrative database. **Methods:** From January 2010 to February 2018, patients hospitalized two or more times for heart failure were selected for analysis. The primary endpoint was the incidence of hospitalizations for heart failure during the follow-up period, which was compared between pimobendan prescription and nonprescription groups after propensity score matching. **Results:** The total number of patients with heart failure included during the study period was 1&#8239;421&#8239;110 and we matched 276 patients in both groups. The incidence of rehospitalization throughout the period to completion of follow-up was 365.23/1000 people/yr (95% confidence interval [CI]: 327.78–402.69) in the pimobendan prescription group and 537.81/1000 people/yr (95% CI: 492.36–583.27) in the non-prescription group. The cumulative incidence at 365 days was significantly lower in the pimobendan prescription group (pimobendan prescription group: 35.4% (95% CI: 29.8–41.8), non-prescription group: 51.2% (95% CI: 45.1–57.7), (P < 0.001). The adjusted hazard ratio in the pimobendan prescription group was 0.556 (95% CI: 0.426–0.725, P < 0.001). **Conclusion:** Pimobendan was suggested to extend the time to rehospitalization for patients with advanced heart failure. It is necessary to verify the results of this study by performing a prospective study. In addition, the influence of pimobendan on general heart failure patients must be examined.
format Article
id doaj-art-eff43459acb9484b8990a132697281f1
institution Kabale University
issn 2327-2236
language English
publishDate 2020-06-01
publisher Columbia Data Analytics, LLC
record_format Article
series Journal of Health Economics and Outcomes Research
spelling doaj-art-eff43459acb9484b8990a132697281f12025-02-10T16:12:48ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362020-06-0171Effects of Pimobendan on Prolonging Time to Rehospitalization or Frequency of Rehospitalization in Patients with Heart Failure: A Retrospective Cohort Study Using a Medical Administrative Database (PREFER Study)Kazuhisa KodamaTatsunori MurataNaoki DohiMasaaki NakanoToshiaki YokoiTomohiro SakamotoKoichi Nakao**Background:** As approximately 24% of patients with chronic heart failure are rehospitalized within 1 year and heart failure is aggravated by repeated hospitalizations, greater importance was attached to the prevention of hospitalization. **Objective:** The objective of this study was to investigate the influence of pimobendan on rehospitalization of patients with advanced heart failure using a Japanese medical administrative database. **Methods:** From January 2010 to February 2018, patients hospitalized two or more times for heart failure were selected for analysis. The primary endpoint was the incidence of hospitalizations for heart failure during the follow-up period, which was compared between pimobendan prescription and nonprescription groups after propensity score matching. **Results:** The total number of patients with heart failure included during the study period was 1&#8239;421&#8239;110 and we matched 276 patients in both groups. The incidence of rehospitalization throughout the period to completion of follow-up was 365.23/1000 people/yr (95% confidence interval [CI]: 327.78–402.69) in the pimobendan prescription group and 537.81/1000 people/yr (95% CI: 492.36–583.27) in the non-prescription group. The cumulative incidence at 365 days was significantly lower in the pimobendan prescription group (pimobendan prescription group: 35.4% (95% CI: 29.8–41.8), non-prescription group: 51.2% (95% CI: 45.1–57.7), (P < 0.001). The adjusted hazard ratio in the pimobendan prescription group was 0.556 (95% CI: 0.426–0.725, P < 0.001). **Conclusion:** Pimobendan was suggested to extend the time to rehospitalization for patients with advanced heart failure. It is necessary to verify the results of this study by performing a prospective study. In addition, the influence of pimobendan on general heart failure patients must be examined.https://doi.org/10.36469/jheor.2020.13246
spellingShingle Kazuhisa Kodama
Tatsunori Murata
Naoki Dohi
Masaaki Nakano
Toshiaki Yokoi
Tomohiro Sakamoto
Koichi Nakao
Effects of Pimobendan on Prolonging Time to Rehospitalization or Frequency of Rehospitalization in Patients with Heart Failure: A Retrospective Cohort Study Using a Medical Administrative Database (PREFER Study)
Journal of Health Economics and Outcomes Research
title Effects of Pimobendan on Prolonging Time to Rehospitalization or Frequency of Rehospitalization in Patients with Heart Failure: A Retrospective Cohort Study Using a Medical Administrative Database (PREFER Study)
title_full Effects of Pimobendan on Prolonging Time to Rehospitalization or Frequency of Rehospitalization in Patients with Heart Failure: A Retrospective Cohort Study Using a Medical Administrative Database (PREFER Study)
title_fullStr Effects of Pimobendan on Prolonging Time to Rehospitalization or Frequency of Rehospitalization in Patients with Heart Failure: A Retrospective Cohort Study Using a Medical Administrative Database (PREFER Study)
title_full_unstemmed Effects of Pimobendan on Prolonging Time to Rehospitalization or Frequency of Rehospitalization in Patients with Heart Failure: A Retrospective Cohort Study Using a Medical Administrative Database (PREFER Study)
title_short Effects of Pimobendan on Prolonging Time to Rehospitalization or Frequency of Rehospitalization in Patients with Heart Failure: A Retrospective Cohort Study Using a Medical Administrative Database (PREFER Study)
title_sort effects of pimobendan on prolonging time to rehospitalization or frequency of rehospitalization in patients with heart failure a retrospective cohort study using a medical administrative database prefer study
url https://doi.org/10.36469/jheor.2020.13246
work_keys_str_mv AT kazuhisakodama effectsofpimobendanonprolongingtimetorehospitalizationorfrequencyofrehospitalizationinpatientswithheartfailurearetrospectivecohortstudyusingamedicaladministrativedatabasepreferstudy
AT tatsunorimurata effectsofpimobendanonprolongingtimetorehospitalizationorfrequencyofrehospitalizationinpatientswithheartfailurearetrospectivecohortstudyusingamedicaladministrativedatabasepreferstudy
AT naokidohi effectsofpimobendanonprolongingtimetorehospitalizationorfrequencyofrehospitalizationinpatientswithheartfailurearetrospectivecohortstudyusingamedicaladministrativedatabasepreferstudy
AT masaakinakano effectsofpimobendanonprolongingtimetorehospitalizationorfrequencyofrehospitalizationinpatientswithheartfailurearetrospectivecohortstudyusingamedicaladministrativedatabasepreferstudy
AT toshiakiyokoi effectsofpimobendanonprolongingtimetorehospitalizationorfrequencyofrehospitalizationinpatientswithheartfailurearetrospectivecohortstudyusingamedicaladministrativedatabasepreferstudy
AT tomohirosakamoto effectsofpimobendanonprolongingtimetorehospitalizationorfrequencyofrehospitalizationinpatientswithheartfailurearetrospectivecohortstudyusingamedicaladministrativedatabasepreferstudy
AT koichinakao effectsofpimobendanonprolongingtimetorehospitalizationorfrequencyofrehospitalizationinpatientswithheartfailurearetrospectivecohortstudyusingamedicaladministrativedatabasepreferstudy